Bayer Warns Planned German Price Curbs May Restrict Drug Access
- Germany looking at revenue ceiling for drugs in first year
- Government also considering extending cap on older drugs
This article is for subscribers only.
Bayer AG, Roche Holding AG and other drugmakers are warning that a German government proposal to tighten price controls on prescription drugs could end up restricting access to new medicines in Europe’s biggest health-care market.
The proposal “lacks a fair balance between measures to foster innovation and cost-containment,” said Dieter Weinand, pharmaceuticals chief at Bayer. “Incremental innovation is not recognized and rewarded adequately.”